Human rabies virus immune globulin

Identification

Name
Human rabies virus immune globulin
Accession Number
DB11603
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Description

IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.

Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine.

IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.

Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Rabies immune globulin
  • Rabies immune globulin (human)
  • Rabies immune globulin human
  • Rabies immune globulin, human
  • Rabies immune globulin,human
  • Rabies immunoglobulins
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hyperab Rabies Immune Globulin HumanLiquid16.5 %IntramuscularCutter Med & Biol, Division Of Miles Canada Ltd.1985-12-311998-09-25Canada
HyperRABInjection, solution300 [iU]/mLInfiltration; IntramuscularGrifols1974-06-12Not applicableUs
Hyperrab S/dInjection150 [iU]/mLIntramuscularGrifols1996-08-14Not applicableUs
Hyperrab S/dSolution150 unitIntramuscularGrifols Therapeutics Inc.1997-10-09Not applicableCanada
Imogam Rabies Inj 150unit/mlLiquid150 unitIntramuscularPasteur mÉrieux Serums Et Vaccins, s.a.1991-12-311999-08-12Canada
Imogam Rabies PasteurizedSolution150 unitIntramuscularSanofi Pasteur Limited1999-04-30Not applicableCanada
Imogam Rabies-HTInjection, solution150 [iU]/mLIntramuscularSanofi Pasteur Limited1984-04-27Not applicableUs
KedrabInjection, solution150 [iU]/mLIntramuscularKedrion Biopharma Inc.2017-11-08Not applicableUs
RabAvertPowder, for solution2.5 unitIntramuscularGlaxosmithkline Inc2005-05-16Not applicableCanada
Categories
UNII
95F619ATQ2
CAS number
Not Available

Pharmacology

Indication

For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine [Label].

Associated Therapies
Pharmacodynamics

Rabies immune globulin prevents viral invasion of the central nervous system.

Mechanism of action

Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system [Label]. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.

TargetActionsOrganism
ARabies lyssavirus
antibody
Rabies lyssavirus
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted [Label].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Human rabies virus immune globulin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Human rabies virus immune globulin.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Human rabies virus immune globulin.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Human rabies virus immune globulin.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Human rabies virus immune globulin.Approved
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Human rabies virus immune globulin.Investigational
AbituzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Human rabies virus immune globulin.Investigational
AdalimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Adalimumab.Approved
AdecatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with Human rabies virus immune globulin.Investigational
AducanumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Human rabies virus immune globulin.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Human rabies virus immune globulin.Approved
AldesleukinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Human rabies virus immune globulin.Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Human rabies virus immune globulin.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human rabies virus immune globulin.Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Human rabies virus immune globulin.Investigational
AlirocumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Human rabies virus immune globulin.Approved
AmatuximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Human rabies virus immune globulin.Approved
AMG 108The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Human rabies virus immune globulin.Approved, Investigational
AnakinraThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anakinra.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Human rabies virus immune globulin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Human rabies virus immune globulin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Human rabies virus immune globulin.Investigational
AnifrolumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Human rabies virus immune globulin.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human rabies virus immune globulin.Approved
ApolizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Human rabies virus immune globulin.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Human rabies virus immune globulin.Investigational
AtezolizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Atezolizumab.Approved, Investigational
AVE9633The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Avelumab.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Human rabies virus immune globulin.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Human rabies virus immune globulin.Approved
BapineuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Human rabies virus immune globulin.Approved, Investigational
BavituximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
BectumomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Human rabies virus immune globulin.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Human rabies virus immune globulin.Approved, Investigational
BelimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with Human rabies virus immune globulin.Approved, Investigational
BesilesomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Besilesomab.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Human rabies virus immune globulin.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bimagrumab.Investigational
BivatuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Human rabies virus immune globulin.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Human rabies virus immune globulin.Approved, Investigational
BlosozumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Human rabies virus immune globulin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with Human rabies virus immune globulin.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Human rabies virus immune globulin.Approved, Investigational
BudesonideThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Budesonide.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Human rabies virus immune globulin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Human rabies virus immune globulin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Human rabies virus immune globulin.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Human rabies virus immune globulin.Approved, Investigational
CaplacizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Caplacizumab.Investigational
Capromab pendetideThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Capromab pendetide.Approved
CarbamazepineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Human rabies virus immune globulin.Approved
CarlumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Carlumab.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Human rabies virus immune globulin.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Human rabies virus immune globulin.Experimental
CatumaxomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Catumaxomab.Approved, Investigational, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Human rabies virus immune globulin.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Human rabies virus immune globulin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Human rabies virus immune globulin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Human rabies virus immune globulin.Approved
CixutumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Human rabies virus immune globulin.Approved, Investigational
ClazakizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clazakizumab.Investigational
ClenoliximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Human rabies virus immune globulin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Human rabies virus immune globulin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Human rabies virus immune globulin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Human rabies virus immune globulin.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Human rabies virus immune globulin.Approved, Investigational
Coltuximab ravtansineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Coltuximab ravtansine.Investigational
ConatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Human rabies virus immune globulin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Human rabies virus immune globulin.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Human rabies virus immune globulin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Human rabies virus immune globulin.Approved, Investigational
CR002The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with CR002.Investigational
CrenezumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Human rabies virus immune globulin.Approved, Investigational
CyclosporineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Human rabies virus immune globulin.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Human rabies virus immune globulin.Approved, Investigational
DacetuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Human rabies virus immune globulin.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Human rabies virus immune globulin.Approved, Investigational
DalotuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Human rabies virus immune globulin.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Human rabies virus immune globulin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Human rabies virus immune globulin.Approved, Investigational
DemcizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Human rabies virus immune globulin.Investigational
DepatuxizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Human rabies virus immune globulin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Human rabies virus immune globulin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Human rabies virus immune globulin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Human rabies virus immune globulin.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Human rabies virus immune globulin.Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Human rabies virus immune globulin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Human rabies virus immune globulin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Human rabies virus immune globulin.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Human rabies virus immune globulin.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Human rabies virus immune globulin.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Human rabies virus immune globulin.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Human rabies virus immune globulin.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Human rabies virus immune globulin.Approved, Investigational
DulaglutideThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dulaglutide.Approved, Investigational
DuligotuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Durvalumab.Approved, Investigational
DusigitumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Human rabies virus immune globulin.Approved, Investigational
EdrecolomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Human rabies virus immune globulin.Approved, Investigational
EldelumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Eldelumab.Investigational
ElotuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Emibetuzumab.Investigational
EmicizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Emicizumab.Approved, Investigational
EnokizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Enokizumab.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Human rabies virus immune globulin.Approved
EpratuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Human rabies virus immune globulin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Human rabies virus immune globulin.Approved
ErenumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Erenumab.Approved, Investigational
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Human rabies virus immune globulin.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Human rabies virus immune globulin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Human rabies virus immune globulin.Approved
EtanerceptThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Etanercept.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Etaracizumab.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Human rabies virus immune globulin.Approved
EtrolizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Everolimus.Approved
EvolocumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Human rabies virus immune globulin.Approved, Investigational
FirategrastThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Human rabies virus immune globulin.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Human rabies virus immune globulin.Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Human rabies virus immune globulin.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Human rabies virus immune globulin.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Human rabies virus immune globulin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Human rabies virus immune globulin.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Human rabies virus immune globulin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Human rabies virus immune globulin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Human rabies virus immune globulin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Human rabies virus immune globulin.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Human rabies virus immune globulin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Human rabies virus immune globulin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Human rabies virus immune globulin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Human rabies virus immune globulin.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Human rabies virus immune globulin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Human rabies virus immune globulin.Approved
Fluticasone propionateThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluticasone propionate.Approved
FontolizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Human rabies virus immune globulin.Approved, Investigational, Withdrawn
FremanezumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fremanezumab.Investigational
FresolimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Human rabies virus immune globulin.Approved, Investigational
GanitumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemtuzumab ozogamicin.Approved, Investigational
GevokizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gevokizumab.Investigational
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Human rabies virus immune globulin.Approved, Investigational
Glembatumumab vedotinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Glembatumumab vedotin.Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Human rabies virus immune globulin.Approved
GS 0573The risk or severity of adverse effects can be increased when GS 0573 is combined with Human rabies virus immune globulin.Investigational
GuselkumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Guselkumab.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Human rabies virus immune globulin.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Human rabies virus immune globulin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Human rabies virus immune globulin.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Human rabies virus immune globulin.Approved
Human cytomegalovirus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Human cytomegalovirus immune globulin.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Hydrocortisone butyrate.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Human rabies virus immune globulin.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Human rabies virus immune globulin.Investigational
IbalizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibalizumab.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human rabies virus immune globulin.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Human rabies virus immune globulin.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Human rabies virus immune globulin.Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Human rabies virus immune globulin.Approved
IdarucizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Human rabies virus immune globulin.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Human rabies virus immune globulin.Approved
IGN311The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Human rabies virus immune globulin.Approved
IMC-1C11The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Human rabies virus immune globulin.Approved, Investigational
InclacumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Human rabies virus immune globulin.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Inotuzumab ozogamicin.Approved, Investigational
Interferon alfa-n3The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-n3.Approved, Investigational
IntetumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ipilimumab.Approved
IratumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Iratumumab.Investigational
IrinotecanThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Irinotecan.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Human rabies virus immune globulin.Investigational
IxekizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Human rabies virus immune globulin.Approved, Investigational, Nutraceutical
LabetuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Human rabies virus immune globulin.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Human rabies virus immune globulin.Approved
LerdelimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Human rabies virus immune globulin.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Human rabies virus immune globulin.Approved, Investigational
Lorvotuzumab mertansineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Human rabies virus immune globulin.Approved
LucatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lucatumumab.Investigational
LumiliximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mavrilimumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Human rabies virus immune globulin.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Human rabies virus immune globulin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Human rabies virus immune globulin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Human rabies virus immune globulin.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Human rabies virus immune globulin.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Human rabies virus immune globulin.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Human rabies virus immune globulin.Approved
MethimazoleThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Human rabies virus immune globulin.Approved
MethylprednisoloneThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Human rabies virus immune globulin.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Human rabies virus immune globulin.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Human rabies virus immune globulin.Investigational
MogamulizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mogamulizumab.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Human rabies virus immune globulin.Approved, Vet Approved
MotavizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Motavizumab.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Human rabies virus immune globulin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Human rabies virus immune globulin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Human rabies virus immune globulin.Approved
MYO-029The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Human rabies virus immune globulin.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Human rabies virus immune globulin.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Human rabies virus immune globulin.Investigational
NebacumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Necitumumab.Approved, Investigational
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Human rabies virus immune globulin.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Human rabies virus immune globulin.Approved, Investigational
NimotuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Human rabies virus immune globulin.Approved, Investigational
OcrelizumabThe therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Human rabies virus immune globulin.Approved, Investigational
OfatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Olaratumab.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Human rabies virus immune globulin.Investigational
OlokizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Olokizumab.Investigational
OnartuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Human rabies virus immune globulin.Approved, Investigational
OzanezumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Human rabies virus immune globulin.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Human rabies virus immune globulin.Approved, Investigational
PalivizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Human rabies virus immune globulin.Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Paquinimod is combined with Human rabies virus immune globulin.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Human rabies virus immune globulin.Approved
PatritumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Human rabies virus immune globulin.Approved
PegaspargaseThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pegaspargase.Approved, Investigational
Peginterferon alfa-2aThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon alfa-2b.Approved
PembrolizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Human rabies virus immune globulin.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Human rabies virus immune globulin.Approved, Investigational
PertuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Human rabies virus immune globulin.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Human rabies virus immune globulin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Human rabies virus immune globulin.Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Human rabies virus immune globulin.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Human rabies virus immune globulin.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Human rabies virus immune globulin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Human rabies virus immune globulin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Human rabies virus immune globulin.Approved, Investigational
PrednisoloneThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Human rabies virus immune globulin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Human rabies virus immune globulin.Approved, Experimental, Investigational
PRO 140The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Human rabies virus immune globulin.Approved, Investigational
R1507The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Human rabies virus immune globulin.Approved, Investigational
RilotumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Human rabies virus immune globulin.Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Human rabies virus immune globulin.Approved
RobatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Human rabies virus immune globulin.Approved
Sacituzumab govitecanThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sacituzumab govitecan.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with Human rabies virus immune globulin.Approved, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Human rabies virus immune globulin.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Human rabies virus immune globulin.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Human rabies virus immune globulin.Experimental, Investigational
SeribantumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Seribantumab.Investigational
SibrotuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Human rabies virus immune globulin.Approved, Investigational
SiplizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Human rabies virus immune globulin.Approved, Investigational
SirukumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Human rabies virus immune globulin.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Human rabies virus immune globulin.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Human rabies virus immune globulin.Approved, Investigational
SulesomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sulesomab.Approved
SulfasalazineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sulfasalazine.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Human rabies virus immune globulin.Approved, Investigational
SYM001The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Human rabies virus immune globulin.Approved, Investigational
TanezumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Human rabies virus immune globulin.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Human rabies virus immune globulin.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Human rabies virus immune globulin.Approved
TeplizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Human rabies virus immune globulin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Human rabies virus immune globulin.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tetanus Immune Globulin.Approved
TetrandrineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tetrandrine.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Human rabies virus immune globulin.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Human rabies virus immune globulin.Approved, Investigational
TildrakizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tildrakizumab.Approved, Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Human rabies virus immune globulin.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Human rabies virus immune globulin.Approved, Withdrawn
TNX-901The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Human rabies virus immune globulin.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Human rabies virus immune globulin.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Human rabies virus immune globulin.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Human rabies virus immune globulin.Approved, Investigational
TovetumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Human rabies virus immune globulin.Approved, Investigational
TralokinumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Human rabies virus immune globulin.Approved, Investigational
TRC105The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Human rabies virus immune globulin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Human rabies virus immune globulin.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Human rabies virus immune globulin.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Human rabies virus immune globulin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Human rabies virus immune globulin.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Human rabies virus immune globulin.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Human rabies virus immune globulin.Approved
VeltuzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Human rabies virus immune globulin.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Human rabies virus immune globulin.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Human rabies virus immune globulin.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Human rabies virus immune globulin.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Human rabies virus immune globulin.Approved, Investigational
VisilizumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Human rabies virus immune globulin.Investigational
VolociximabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Volociximab.Investigational
WortmanninThe risk or severity of adverse effects can be increased when Wortmannin is combined with Human rabies virus immune globulin.Experimental
XmAb 2513The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with XTL-001.Investigational
ZidovudineThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Zidovudine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911213
AHFS Codes
  • 80:04.00 — Serums
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentRabies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntramuscular16.5 %
Injection, solutionInfiltration; Intramuscular300 [iU]/mL
InjectionIntramuscular150 [iU]/mL
SolutionIntramuscular150 unit
LiquidIntramuscular150 unit
Injection, solutionIntramuscular150 [iU]/mL
Powder, for solutionIntramuscular2.5 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

1. Rabies lyssavirus
Kind
Organism
Organism
Rabies lyssavirus
Pharmacological action
Yes
Actions
Antibody

Drug created on June 01, 2016 14:49 / Updated on August 15, 2018 09:58